Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Predictive Oncology Inc (POAI) USD0.01

Sell:$0.85 Buy:$0.87 Change: $0.0816 (8.70%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Change: $0.0816 (8.70%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Change: $0.0816 (8.70%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Predictive Oncology Inc. is focused on applying artificial intelligence (AI) to personalized medicine and drug discovery. It operates through its subsidiaries, Helomics Holding Corporation (Helomics), TumorGenesis Inc., Skyline Europe and Skyline Medical Inc. Helomics applies AI to its data gathered from patient tumors to both personalize cancer therapies for patients and focusses on the development of new-targeted therapies. Helomics’ clinical laboratory improvement amendments (CLIA)-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions. Its TumorGenesis Inc. is engaged in developing approach to tumors in the laboratory. Skyline Medical Inc. markets its STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions.

Contact details

2915 Commers Dr Ste 900
United States
+1 (651) 3894800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$14.46 million
Shares in issue:
15.42 million
Health Care Supplies
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Carl Schwartz
    President, Chief Executive Officer, Director
  • Robert Myers
    Chief Financial Officer
  • David Johnson
    Senior Vice President - Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.